

**AMENDMENT UNDER 37 C.F.R. § 1.121(C)**

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-49 (Cancelled)

Claim 50 (Currently Amended) A process for treating a disease in a mammalian subject comprising administering to said subject an effective amount of a mammalian metabolite so as to modulate or change at least one component in the immune system of said subject, wherein the mammalian metabolite is a glycolipid, and wherein the disease includes a defect in an immune response as part of the pathogenesis of the disease.

Claim 51 (Original) The process of claim 50, wherein said immune system component comprises cellular, humoral or cytokine elements.

Claim 52 (Original) The process of claim 50, wherein said modulation or change is specific or non-specific.

Claim 53 (Cancelled)

Claim 54 (Cancelled)

Claim 55 (Currently Amended) The process of claim 50, 54, wherein said glycolipid comprises a monosaccharide ceramide.

Claim 56 (Original) The process of claim 55, wherein said monosaccharide ceramide comprises a glucosyl ceramide and galatosyl ceramide.

Claim 57 (Original) The process of claim 50, wherein said administering step is carried

out by means comprising intravenous means, intra-muscular means, subcutaneous means, intra-peritoneal means or oral means.

Claim 58 (Original) The process of claim 50, wherein said disease comprises cancer, an infection or immune dysfunction.

Claim 59 (Original) The process of claim 58, wherein said infection is viral or bacterial.

Claim 60 (Original) The process of claim 59, wherein said viral infection comprises HBV, HCV or HIV.

Claim 61 (Withdrawn) The process of claim 58, wherein said immune dysfunction comprises diabetes type I, diabetes type II, rheumatoid arthritis, Crohn's disease, arteriosclerosis and ulcerative colitis.

Claim 62 (Original) The process of claim 50, wherein said mammalian subject comprises a human.